微小残留病监测在B细胞淋巴瘤中的研究进展  

Progress of minimal residual disease surveillance in B-cell lymphoma

作　　者：黄燕姗 邱录贵 易树华 Huang Yanshan;Qiu Lugui;Yi Shuhua(Haihe Laboratory of Cell Ecosystem,National Clinical Research Center for Blood Diseases,State Key Laboratory of Experimental Hematology,Chinese Academy of Medical Sciences&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Institute of Hematology,Tianjin 300020,China)

机构地区：[1]中国医学科学院血液病医院(中国医学科学院血液学研究所)、实验血液学国家重点实验室、国家血液系统疾病临床医学研究中心细胞生态海河实验室,天津300020

出　　处：《白血病．淋巴瘤》2023年第6期373-377,共5页Journal of Leukemia & Lymphoma

基　　金：中国医学科学院医学与健康科技创新工程(2021-I2M-C&T-B-081);国家自然科学基金(81970187, 82170193, 81900203)。

摘　　要：B细胞淋巴瘤是一组起源于B细胞的具有异质性的血液系统恶性肿瘤, 分为侵袭性B细胞淋巴瘤和惰性B细胞淋巴瘤。虽然疾病缓解率很高, 但部分患者仍会复发进展, 因此治疗后定期监测及早期识别肿瘤复发具有重要意义。当前的诊疗中, 淋巴瘤的复发主要依靠影像学和临床评估, 而部分研究显示基于流式细胞术或二代测序等手段的微小残留病(MRD)检测可以更加准确评估疾病缓解深度及判断预后, 同时早期识别疾病复发。文章围绕MRD监测在惰性淋巴瘤和侵袭性淋巴瘤中的应用现状展开综述, 主要包括MRD的检测方法及其在不同淋巴瘤中的研究现状及应用前景。B-cell lymphoma is a group of heterogeneous hematologic malignant tumors originating from B cells,and it could be divided into invasive B-cell lymphoma and inert B-cell lymphoma.Currently,although disease remission rate has reached a high level,some patients still develop disease relapse or progression,thus,it is important to regularly monitor the disease and early identify the recurrence.At present,the recurrence of lymphoma mainly depends on imaging and clinical evaluation.However,some studies have shown that the minimal residual disease(MRD)monitoring based on flow or second-generation sequencing can provide a more accurate assessment of the depth of remission,predict the disease prognosis,and identify the early disease recurrence.This review summarizes the application of MRD in indolent lymphoma and aggressive lymphoma,mainly including the detection methods of MRD,research status and the application prospect of MRD in different lymphomas.

关 键 词：淋巴瘤 B细胞 微小残留病 血液系统疾病 分子靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]